A Prospective Controlled Study of Serum suPAR in the CsA-treated FSGS Patients
A Prospective Controlled Study of Serum suPAR in the CsA-treated FSGS Patients
The purpose of this study is to determine whether the improved responsiveness to treatment
 achieved by CsA in patients with steroid-resistant or steroid-dependent FSGS could be
 explained by CsA's inhibitory action on the circulating suPAR expression.
Inclusion Criteria:

 -  Age at entry is between 14 and 70 years

 -  biopsy-proven primary FSGS

 -  proteinuria >=3 g/day

 -  without corticosteroids or CsA treatment before entry

 Exclusion Criteria:

 -  Chronic Inflammatory Diseases

 -  malignant tumor

 -  diabetes mellitus

 -  contraindications for the treatment of corticosteroids or CsA treatment

 -  untolerate to or unwilling to accept corticosteroids or CsA treatment